X @Cathie Wood

Industry Focus - CRISPR gene editing represents a significant biology breakthrough with substantial potential value [1] - ARK Invest believes one-time cures can be a good business, contrary to many analysts' opinions [1] Market Opportunity - Cardiovascular disease is the world's leading cause of death [1] - CRISPR-based therapies targeting lipid metabolism genes could reshape prevention and open a ~$2.8 trillion market [1] Companies Mentioned - Companies mentioned include $CRSP, $NTLA, $BEAM, and $PRME [1]